Dr. Deanna Gibson’s research in gut microbiome research is paving the path for a new class of therapeutics that can harness beneficial bacteria to treat inflammatory bowel disease, diabetes and mood disorders.
Groundbreaking technology created by a UBC Okanagan biology professor is leading the development of new medicine that can help improve gut health.
Dr. Deanna Gibson, with UBC Okanagan’s Irving K. Barber Faculty of Science, leads a research lab that investigates the intricate relationship between the gut microbiome and human health.
Dr. Gibson is a leading authority in gut microbiome research and is also a driving force behind Melius MicroBiomics, a biotech company focused on harnessing the power of the gut microbiome for improved health.
Now, her entrepreneurial spirit and deep expertise are propelling the company to the forefront of the field by developing innovative therapies for various health conditions, explains Rob Emlyn, CEO and Co-Founder of Melius MicroBiomics.
“We are thrilled to collaborate with UBC, a global leader in scientific innovation,” Emlyn says. “This agreement will significantly advance our Genetically Engineered Microbial Medicine (GEMM) platform, and bring us closer to developing transformative treatments for patients in need.”
Read the full story here: UBC Okanagan News